Physician profile
Mark P Borsheim
NPI 1396728135
$1,309.78
in general payments reported to CMS, 2019-2025
17 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $57.55 · 2022: $34.38 · 2023: $470 · 2024: $63.57 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.89 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $253.62 | 2022-2023 | Qulipta, Ubrelvy, Linzess |
| Pfizer INC. | $225.30 | 2019-2023 | |
| Amgen INC. | $173.10 | 2019-2024 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $142.78 | 2019-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $78.54 | 2019-2025 | |
| Exact Sciences Corporation | $72.62 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $71.80 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astellas Pharma US INC | $68.40 | 2019-2023 | Veozah |
| Pacira Therapeutics, INC. | $44.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.98 | 2020-2023 | Jardiance |
| Genzyme Corporation | $30.26 | 2025 | |
| Merck Sharp & Dohme LLC | $27.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.98 | 2019 | |
| Horizon Therapeutics Plc | $18.46 | 2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $16.72 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.93 | 2019 | |
| Medtronic Vascular, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Borsheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.